Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 151 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Probe drugs Clear all
Terminated Not applicable Interventional Results available

Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration

NCT02568189
View directory record Official record
Conditions
Sepsis, Gastroenteritis, Dehydration
Interventions
SonoSite Maxx Series Ultrasound System
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Up to 21 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 3, 2026, 1:00 PM EDT
Terminated Not applicable Interventional

Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With Endobronchial Obstruction

NCT03564054
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Photodynamic Therapy, Argon Plasma Coagulation
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

NCT06679413
View directory record Official record
Conditions
Healthy Study Participants
Interventions
midazolam, metformin, bupropion, fenfluramine HCl
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 3, 2026, 1:00 PM EDT
Active, not recruiting Not applicable Interventional

The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System

NCT06206746
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility, Female
Interventions
May Health System
Device
Lead sponsor
May Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
19
States / cities
Encino, California • San Francisco, California • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 3, 2026, 1:00 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Smoking Cessation CM for Veterans With or at Risk for Cancer

NCT06432985
View directory record Official record
Conditions
Tobacco Use Disorder, Substance Use Disorder
Interventions
Focus Group, Contingency Management, Behavioral Counseling (Cognitive Behavioral Therapy, CBT), TUD Treatment as Usual (TAU)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

NCT03987503
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes

NCT01473888
View directory record Official record
Conditions
Stable Angina
Interventions
T89(Dantonic)
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers

NCT00752843
View directory record Official record
Conditions
Healthy Subjects
Interventions
mifepristone + fluvastatin
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 3, 2026, 1:00 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Physical Exam, Static & Dynamic Ultrasound Assessment, & Treatment of Thoracolumbar Fascia (TLF) Mediated Low Back Pain

NCT06818175
View directory record Official record
Conditions
Low Back Pain, Chronic Low-back Pain, Acute Low Back Pain
Interventions
Ultrsound Guided Hydrodissection of the Thoracolumbar Fascia, Osteopathic Manipulative Treatment (OMT)
Procedure
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Gepotidacin

NCT04493931
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Results available

Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer

NCT02287675
View directory record Official record
Conditions
Breast Cancer
Interventions
Lymphoseek, Sulfur Colloid
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants

NCT06677957
View directory record Official record
Conditions
Healthy Participants
Interventions
Digoxin, Divarasib, Rosuvastatin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

NCT05067439
View directory record Official record
Conditions
Healthy Participants
Interventions
Abrocitinib, Omeprazole, Caffeine, Efavirenz
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

NCT05652660
View directory record Official record
Conditions
Healthy
Interventions
ARV-471, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

NCT01462318
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab)
Drug · Other · Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Early Phase 1 Interventional

Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors

NCT00816335
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PET/CT scan, 18F-FDG Injection, Preoperative 18F-FDG PET/CT Scan, 18F-FDG for patients with Bladder Cancer, Surgical Procedure, Specimen PET/CT Scan
Procedure · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 3, 2026, 1:00 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of Neural Constraints on Movement in Stroke

NCT06666673
View directory record Official record
Conditions
Stroke
Interventions
Tizanidine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 3, 2026, 1:00 PM EDT
Not yet recruiting Early Phase 1 Interventional

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

NCT07389525
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma, Melanoma
Interventions
ICI Therapy
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

NCT00357448
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Sep 3, 2026, 1:00 PM EDT
Recruiting No phase listed Observational

Endometriosis Pain

NCT06101303
View directory record Official record
Conditions
Pelvic Pain, Endometriosis
Interventions
Psychophysical assessment, Psychophysical assessments of experimental pain, Blood, urine and saliva samples, Biopsy and surgery-related data.
Other · Behavioral · Diagnostic Test + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Daily Stress and Vascular Function in Midlife as a Risk Factor for Cognitive Decline

NCT06466655
View directory record Official record
Conditions
Middle-aged Adults, Major Depressive Disorder
Interventions
MitoTempol, Lactated Ringer's (control)
Drug
Lead sponsor
University of Delaware
Other
Eligibility
40 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

NCT01596647
View directory record Official record
Conditions
Advanced Solid Tumors, Excluding Breast Cancer
Interventions
caffeine, diclofenac, omeprazole, midazolam, TKI258
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Kansas City, Kansas • Detroit, Michigan • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 3, 2026, 1:00 PM EDT
Not yet recruiting Phase 2 Interventional

Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

NCT07620548
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 3, 2026, 1:00 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection

NCT05144828
View directory record Official record
Conditions
Pain, Postoperative, Lung Diseases
Interventions
Intercostal Nerve Cryoablation, Patient-controlled analgesia (PCA)
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 3, 2026, 1:00 PM EDT